Fatty Liver Disease Clinical Trials 2023

What are the top hospitals conducting fatty liver disease research?

Fatty liver disease, a condition characterized by the accumulation of fat in the liver, has become a significant health concern worldwide. Fortunately, several top hospitals are leading the way in conducting clinical trials to better understand and effectively treat this condition. In Boston, Massachusetts General Hospital stands out with its six ongoing trials and extensive experience of 24 completed fatty liver disease studies. Since initiating their first trial in 2010, this renowned institution has been deeply committed to unraveling the complexities of this disease.

Moving across the country to Rialto, California, we find another dedicated facility making strides in fatty liver disease research. The Inland Empire Liver Foundation is currently undertaking six active clinical trials while boasting an impressive track record of 28 completed studies since starting their exploration into this field in 2015.

Meanwhile, on the sunny shores of Lakewood Ranch in Florida, the Florida Research Institute is also actively engaged in six ongoing clinical trials focused on fatty liver disease. This relatively new player—having recorded its first trial just five years ago—demonstrates remarkable commitment to advancing our understanding and treatment options for this condition.

Heading further west to Fresno Clinical Research Center located within California's Central Valley region - they too have made valuable contributions through their dedication toward combating fatty liver diseases via engaging themselves into five present-day investigations complemented by twelve previously held experiments since 2015.

Lastly but certainly not least,Duke University Medical Center situated at Durham specializes not only as one among leading academic medical institutions but similarly offers hope for individuals affected by Fatty Liver Disease. With an admirable count of five active clinical tests alongside twenty-seven prior conducted examinations from as early as2005; Duke demonstrates unwavering determination towards unlocking potential solutions against such ailments through extensive research endeavors.The collaborative efforts showcased by these various hospitals signify that groundbreaking progress can be achieved when experts unite forces with shared goals.Through continuous exploration and innovative approaches,future treatments may emerge providing relief and renewed hope for those affected by fatty liver disease.

Which are the best cities for fatty liver disease clinical trials?

When it comes to fatty liver disease clinical trials, several cities emerge as prominent locations for ongoing research. San Antonio, Texas leads the way with 63 active trials investigating treatments like VK2809, AXA1125, and Tirzepatide. Miami, Florida closely follows with 59 trials studying IVA337, Study 1 ALN-HSD Low Dose, Obeticholic Acid, among others. Los Angeles in California showcases 30 active trials exploring interventions such as PF-06865571 and Obeticholic Acid. Additionally,Tucson in Arizona presents a promising hub with 29 studies focusing on treatments like MGL-3196 and Semaglutide (SEMA). Lastly, New york City contributes to the advancement of knowledge through its collection of 28 active trials targeting belapectin, PF-06865571,and Tirzepatide. These cities serve as crucial centers for cutting-edge research aimed at combatting fatty liver disease effectively.

Which are the top treatments for fatty liver disease being explored in clinical trials?

Clinical trials are shedding light on the most promising treatments for fatty liver disease. Semaglutide, a drug that made its debut in 2016, is currently being explored in four active trials and has been part of 11 clinical studies dedicated to this condition. Pioglitazone, first listed in 2002, is another contender with two ongoing trials and a total of 13 fatty liver disease studies under its belt. Lastly, EFX, introduced just last year in 2019, shows potential as it participates in two active trials among three all-time clinical investigations focused on combating fatty liver disease. These advancements offer hope for those suffering from this prevalent health issue.

What are the most recent clinical trials for fatty liver disease?

Recent clinical trials offer hope for individuals with fatty liver disease, paving the way for potential advancements in treatment. Of note are Part 1 Group 2 and LY3885125 (Part A), both Phase 1 trials that explore novel therapeutic approaches to combat this condition. Additionally, Reduction toward euinsulinemia (RE) protocol and BI 3006337 dose group 4 investigate new strategies to reduce insulin levels in patients with fatty liver disease. Another notable trial involves Diazoxide oral suspension at a specific dosage per weight, offering a fresh perspective on potential treatment options. These studies mark significant progress in our understanding of fatty liver disease and hold promise for improved patient outcomes moving forward.

What fatty liver disease clinical trials were recently completed?

Several clinical trials focusing on fatty liver disease have recently been concluded, reflecting the continuous efforts to combat this condition. Notably, Altimmune, Inc. completed two trials for ALT-801 in September 2021 and March 2022 respectively. In addition, BIO89-100 trial by 89bio, Inc., Efinopegdutide 20 mg/mL trial by Merck Sharp & Dohme Corp., AMG 609 trial by Amgen, TERN-201 trial by Terns, Inc., and ORMD-0801 (Insulin) capsule 8 mg BD trial sponsored by Oramed Ltd were all finished between August and November of either 2020 or 2021. These diverse studies signify the dedication of researchers across different organizations in their pursuit of effective treatments for fatty liver disease.